drugset / Trial / NCT07439211
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is to evaluate the safety and preliminary efficacy of adding the PI3K-gamma inhibitor, eganelisib, to a standard of care treatment option with combination venetoclax and azacitidine in participants with acute myeloid leukemia (AML). The names of the study drugs involved in this research study are: * Venetoclax (a type of BCL-2 inhibitor) * Azacitidine (a type of Demethylating Agent) * Eganelisib (a type of PI3K-gamma inhibitor)
Timeline
- Start
- 2026-07
- Primary completion
- 2028-02-01
- Completion
- 2029-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | eganelisib | Small molecule | — | Oral |
| Background | Azacitidine | Other / unclassified | — | Subcutaneous |
| Background | Venetoclax | Small molecule | — | Oral |